Molecular Characterization of Carbapenem-Nonsusceptible Enterobacterial Isolates Collected During a Prospective Interregional Survey in France and Susceptibility to the Novel Ceftazidime-Avibactam and Aztreonam-Avibactam Combinations
Overview
Authors
Affiliations
An interregional surveillance program was conducted in the northwestern part of France to determine the prevalence of carbapenem-nonsusceptible Enterobacteriaceae (CNSE) isolates and their susceptibility to ceftazidime-avibactam and aztreonam-avibactam combinations. Nonduplicate CNSE clinical isolates were prospectively collected from six hospitals between June 2012 and November 2013. MICs of ceftazidime and aztreonam, alone or combined with a fixed concentration of avibactam (4 μg/ml), and those of carbapenems (comparator agents) were determined. MICs of ertapenem in combination with phenylalanine arginine-naphthylamide dihydrochloride (PAβN) were also determined to assess active efflux. Genes encoding carbapenemases, plasmid-mediated AmpC enzymes, extended-spectrum β-lactamases (ESBLs), and major outer membrane proteins (OMPs) were amplified and sequenced. OMPs were also extracted for SDS-PAGE analysis. Among the 139 CNSE isolates, mainly Enterobacter spp. and Klebsiella pneumoniae, 123 (88.4%) were ertapenem nonsusceptible, 12 (8.6%) exhibited reduced susceptibility to all carbapenems, and 4 Proteeae isolates (2.9%) were resistant to imipenem. Carbapenemase production was detected in only two isolates (producing OXA-48 and IMI-3). In contrast, OMP deficiency, in association with AmpCs and/or ESBLs (mainly CTX-M-9, SHV-12, and CTX-M-15), was largely identified among CNSE isolates. The ceftazidime-avibactam and aztreonam-avibactam combinations exhibited potent activity against CNSE isolates (MIC50/MIC90, 1/1 μg/ml and 0.5/0.5 μg/ml, respectively) compared to that of ceftazidime and aztreonam alone (MIC50/MIC90, 512/512 μg/ml and 128/512 μg/ml, respectively). This study reveals the in vitro activity of ceftazidime-avibactam and aztreonam-avibactam combinations against a large collection of porin-deficient enterobacterial isolates that are representative of the CNSE recovered in the northern part of France.
Mammeri H, Sereme Y, Toumi E, Faury H, Skurnik D PLoS Pathog. 2025; 21(2):e1012902.
PMID: 39919103 PMC: 11805372. DOI: 10.1371/journal.ppat.1012902.
Sui X, Guo L, Bao Z, Xian M, Zhao G Microorganisms. 2025; 13(1).
PMID: 39858970 PMC: 11767505. DOI: 10.3390/microorganisms13010202.
Lee Y, Ponnampalavanar S, Wong J, Kong Z, Ngoi S, Karunakaran R Front Cell Infect Microbiol. 2024; 14:1464816.
PMID: 39359938 PMC: 11445613. DOI: 10.3389/fcimb.2024.1464816.
Wong D Antibiotics (Basel). 2024; 13(8).
PMID: 39200065 PMC: 11350918. DOI: 10.3390/antibiotics13080766.
Zhao J, Pu D, Li Z, Zhang Y, Liu X, Zhuo X Virulence. 2024; 15(1):2348251.
PMID: 38697754 PMC: 11067985. DOI: 10.1080/21505594.2024.2348251.